Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Reading miRNAs for Clinical Meaning
Single miRNAs Don’t Say Much, but They May Become Eloquent Biomarkers if We Take Their Testimony in Context
Sorting Out the CRISPR Patent Case
Sounds of Science Podcast
Good Assays for Bad Immunogenicity
Avoid “Bad” Immunogenicity by Using Assays That Are More Sensitive and Can Adapt to Increasingly Complex and Specialized Drugs
For full access to this article login to GEN Select now.
Regenerative Therapies Gain Momentum
Initiatives Include Treating Diseases and Conditions by Restoring or Repairing Genetic and Cellular Defects
- Advances in stem cell research and tissue engineering are evolving into a new generation of regenerative therapies to treat diseases and conditions by restoring or repairing genetic and cellular defects. The clinical development stakes are high, but the results have been some fruitful collaborations between pharma and biotech. ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.